Boehringer Ingelheim Vetmedica Gmbh

Other

Boehringer Ingelheim International Gmbh

Janine Lamar

Michael Aven

Balazs Albrecht

Ingo Lang

Steven John Padula

Matthias Hausmann

Benjamin Franzmann

Sudha Visvanathan

Christian Thoma

Jay Fine

Meera Ramanujam

USE OF ANTI-IL-36R ANTIBODIES FOR TREATMENT OF GENERALIZED PUSTULAR PSORIASIS

The present invention provides methods for treating, preventing or ameliorating a neutrophilic dermatosis. The methods of the present invention include administering to a patient suffering from a neutrophilic dermatosis a pharmaceutical composition including an anti-interleukin-36 receptor (anti-IL-36R) antibody.

Anti-IL-36R antibodies for the treatment of pyoderma gangrenosum

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to a pharmaceutical (medicament) formulation of glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof.

Pharmaceutical formulation comprising ciclesonide

The disclosure relates to the field of medicine, in particular to the field of veterinary medicine. The disclosure specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (LAMAs)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD) in animals, preferably equines such as horses.

Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses

Methods of treating airway diseases in equines include administering to an equine an effective amount of ciclesonide or a pharmaceutically acceptable salt thereof or a composition including ciclesonide or a pharmaceutically acceptable salt thereof.

Ciclesonide for the treatment of airway disease in horses

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (LAMAs)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD) in animals, preferably equines such as horses.

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative or salt thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).

The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof, for the treatment of airway disease in horses, such as pulmonary disease, preferably recurrent airway obstruction (RAO), Summer Pasture Associated Obstructive Pulmonary disease (SPAOPD), and inflammatory airway disease (IAD).

Growing community of inventors

Ingelheim am Rhein, Germany

Janine Lamar